Collegium Pharmaceutical (COLL) Total Debt (2014 - 2026)

Collegium Pharmaceutical's Total Debt history runs 13 years deep, the most recent figure standing at $564.3 million for Q1 2026.

• On a quarterly basis, Total Debt rose 0.73% year-over-year to $564.3 million in Q1 2026; TTM through Mar 2026 was $564.3 million, a 0.73% increase from a year earlier, with the FY2025 full-year figure at $571.1 million, down 7.18% from the prior year.
• Total Debt retreated to $564.3 million in Q1 2026 per COLL's latest filing, from $571.1 million in the prior quarter.
• Across five years, Total Debt topped out at $630.3 million in Q3 2024 and bottomed at $316.2 million in Q2 2024.
• The 5-year median for Total Debt is $560.3 million (2025), against an average of $527.7 million.
• Across the five-year window, Total Debt jumped 409.07% in 2022 and plunged 35.9% in 2024, its largest moves.
• Year by year, Total Debt stood at $560.1 million in 2022, then decreased by 27.68% to $405.0 million in 2023, then soared by 51.91% to $615.3 million in 2024, then declined by 7.18% to $571.1 million in 2025, then fell by 1.18% to $564.3 million in 2026.
• Per Business Quant, the three latest COLL Total Debt figures stand at $564.3 million (Q1 2026), $571.1 million (Q4 2025), and $505.6 million (Q3 2025).